Literature DB >> 20739785

Progressive myoclonic epilepsy.

P Satishchandra1, S Sinha.   

Abstract

Progressive myoclonic epilepsy (PME) is a disease complex and is characterized by the development of relentlessly progressive myoclonus, cognitive impairment, ataxia, and other neurologic deficits. It encompasses different diagnostic entities and the common causes include Lafora body disease, neuronal ceroid lipofuscinoses, Unverricht-Lundborg disease, myoclonic epilepsy with ragged-red fiber (MERRF) syndrome, sialidoses, dentato-rubro-pallidal atrophy, storage diseases, and some of the inborn errors of metabolism, among others. Recent advances in this area have clarified molecular genetic basis, biological basis, and natural history, and also provided a rational approach to the diagnosis. Most of the large studies related to PME are from south India from a single center, National Institute of Mental Health and Neurological Sciences (NIMHANS), Bangalore. However, there are a few case reports and small series about Lafora body disease, neuronal ceroid lipofuscinoses and MERRF from India. We review the clinical and research experience of a cohort of PME patients evaluated at NIMHANS over the last two decades, especially the phenotypic, electrophysiologic, pathologic, and genetic aspects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20739785     DOI: 10.4103/0028-3886.68660

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  11 in total

Review 1.  Drug Treatment of Progressive Myoclonic Epilepsy.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

Review 2.  KCTD7-related progressive myoclonic epilepsy: report of three Indian families and review of literature.

Authors:  Dhanya Lakshmi Narayanan; Puneeth H Somashekar; Purvi Majethia; Anju Shukla
Journal:  Clin Dysmorphol       Date:  2022-01-01       Impact factor: 0.816

Review 3.  Myoclonus-Ataxia Syndromes: A Diagnostic Approach.

Authors:  Malco Rossi; Sterre van der Veen; Marcelo Merello; Marina A J Tijssen; Bart van de Warrenburg
Journal:  Mov Disord Clin Pract       Date:  2020-11-03

4.  Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis.

Authors:  Luca Vignatelli; Francesca Bisulli; Federica Pondrelli; Lorenzo Muccioli; Laura Licchetta; Barbara Mostacci; Corrado Zenesini; Paolo Tinuper
Journal:  Orphanet J Rare Dis       Date:  2021-08-16       Impact factor: 4.123

5.  Epilepsy: Indian perspective.

Authors:  Nandanavana Subbareddy Santhosh; Sanjib Sinha; Parthasarathy Satishchandra
Journal:  Ann Indian Acad Neurol       Date:  2014-03       Impact factor: 1.383

6.  Reduced ceramide synthase 2 activity causes progressive myoclonic epilepsy.

Authors:  Mai-Britt Mosbech; Anne S B Olsen; Ditte Neess; Oshrit Ben-David; Laura L Klitten; Jan Larsen; Anne Sabers; John Vissing; Jørgen E Nielsen; Lis Hasholt; Andres D Klein; Michael M Tsoory; Helle Hjalgrim; Niels Tommerup; Anthony H Futerman; Rikke S Møller; Nils J Færgeman
Journal:  Ann Clin Transl Neurol       Date:  2014-01-13       Impact factor: 4.511

7.  Juvenile Myoclonic Epilepsy Presenting with Neurocognitive Impairment: A Case Report.

Authors:  Sarfraz Mahesar; Hira F Akbar; Husnain Abid; Rabia Sana
Journal:  Cureus       Date:  2018-03-05

8.  Medical management of a child with congenital generalized lipodystrophy accompanied with progressive myoclonic epilepsy: A case report.

Authors:  Yi Zhang; Xiaofei Chen; Feixiang Luo; Lihua Jiang; Jialu Xu; Shuohui Chen
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

9.  Periodic electroencephalogram discharges in a case of Lafora body disease: An unusual finding.

Authors:  Rajendra Singh Jain; Arti Gupta; Pankaj Kumar Gupta; Rakesh Agrawal
Journal:  Ann Indian Acad Neurol       Date:  2016 Apr-Jun       Impact factor: 1.383

10.  Progressive Myoclonic Epilepsy Due to Lafora Body Disease with a Novel Mutation.

Authors:  Anil V Israni; Anirban Mandal
Journal:  J Pediatr Neurosci       Date:  2018 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.